30th May 2022 18:14
Genedrive PLC - Manchester-based molecular diagnostics company - Says the UK Medicines & Healthcare Products Regulatory Agency has granted a coronavirus test device approval enabling the sale of the Genedrive COV19-ID Kit in the UK. Genedrive's application for approval was made on December 21.
Chief Executive David Budd says: "We are very pleased to have received a CTDA, which now allows the UK access to the fastest point-of-care COVID molecular test. The performance of the test has met CTDA standards in all regards, which positions genedrive well to engage in opportunities as they develop going forwards in the UK."
Current stock price: 23.75 pence
12-month change: down 64%
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Genedrive